Pathological workup of surgical breast cancer specimens after neoadjuvant chemotherapy

Breast Care

Volumn 1, Issue 6, 2006, Pages 368-373

  Denkert, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Neoadjuvant; Pathological complete remission; Pathology

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; INTERDISCIPLINARY COMMUNICATION; LYMPH NODE; PRIORITY JOURNAL; PUNCH BIOPSY; REVIEW; TUMOR REGRESSION; TUMOR VOLUME;

EID: 33845880408     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000097890     Document Type: Review

References (21)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-8, review.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9.
3. Von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, Zuna I, Costa SD; German Breast Group: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005;16:56-63.
4. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-6.
5. Amat S, Abrial C, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Cure H, Chollet P: High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255-63.
6. Anderson BO: Pathologic response to preoperative systemic therapy: the new biological paradigm for predicting outcome and planning therapy. Ann Surg Oncol 2003;10:713-5.
7. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinischen Fachgesellschaften: Diagnostik, Therapie und Nachsorge des Mammakarzinoms - eine nationale S3 Leitlinie. www.krebsgesellschaft.de/ Leitlinien Mammakarzinom.
8. The Association of Directors of Anatomic and Surgical Pathology: ADASP Checklists for Surgical Pathology Reports of Malignant Neoplasms. www.adasp.org.
9. Tavassoli, F, Devilee P (eds): WHO Classification of Tumors - Pathology and Genetics of Tumours of Breast and Female Genital Organs. Lyon, IARC Press, 2003.
10. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF: Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie. Geburtshilfe Frauenheilkd 1994;54:552-8.
11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
12. Wittekind Ch, Meyer HJ, Bootz F: TNM Klassifikation maligner Tumoren, 6. Auflage. Berlin, Springer, 2003.
13. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
14. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40.
15. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
16. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M, Tsuda H, Commitee for Production of Histopathological Criteria, Japanese Breast Cancer Society: Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001;8:1-2.
17. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320-7.
18. Länger F, Lück H-J, Kreipe HH: Therapieinduzierte Tumorregression beim Mammakarzinom. Pathologe 2004;25:455-460.
19. Länger F, Lück H-J, Kreipe HH: Therapieinduzierte Tumorregression beim Mammakarzinom. Pathologe 2004;25:455-460.
20. Sinn HP, Magener A, Durr F, Harcos A, von Minckwitz G: Predictive and prognostic factors in breast cancer evaluated by immunohistological methods Verh Dtsch Ges Pathol 2001;85:200-5.
21. Amat S, Penault-Llorca F, Cure H, Le Bouedec G, Achard JL, van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P: Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791-6.